Pivotal odronextamab (cd20xcd3) phase 2 data in patients with relapsed/refractory diffuse large b-cell lymphoma debut at ash

49% objective response rate (orr) in heavily pre-treated patients who were naÏve to prior car-t, with 31% achieving a complete response (cr) even in patients who received prior car-t, 48% orr and 32% cr observed in a dose expansion cohort from a phase 1 trial data will form the basis of regulatory submissions planned for 2023 tarrytown, n.y. , dec. 11, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive new and updated data from a phase 1 and pivotal phase 2 trial (elm-1 and elm-2) evaluating investigational odronextamab in patients with relapsed/refractory (r/r) diffuse large b-cell lymphoma (dlbcl).
REGN Ratings Summary
REGN Quant Ranking